Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļODTX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļOdyssey Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 08, 2026
āļāļĩāļāļĩāđāļGlick (Gary D)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ151
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļMay 08
āļāļĩāđāļāļĒāļđāđ51 Sleeper Street
āđāļĄāļ·āļāļBOSTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02210
āđāļāļĢāļĻāļąāļāļāđ16178659628
āđāļ§āđāļāđāļāļāđhttps://odysseytx.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļODTX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļMay 08, 2026
āļāļĩāļāļĩāđāļGlick (Gary D)
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Ian F. Smith, CPA
Independent Director
Mr. Jason Haas
Chief Financial Officer
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Ms. Nia Tatsis, Ph.D.
Independent Director
Ms. Ksenija Ksenija
Independent Director
Dr. Valerie Odegard, Ph.D.
Dr. Valerie Odegard, Ph.D.
Independent Director
Dr. Carolyn Ng, Ph.D.
Independent Director
Mr. Nan Li
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Ian F. Smith, CPA
Independent Director
Mr. Jason Haas
Chief Financial Officer
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Ms. Nia Tatsis, Ph.D.
Independent Director